Advertisement
ALNY vs ARGX
Which Stock Would AI Choose? Alnylam Pharmaceuticals (ALNY) vs. argenx SE (ARGX) Stock Comparison
Key Takeaways
- ALNY has delivered stronger year-to-date returns compared with ARGX, supported by robust product revenue growth in recent quarters.
- Both companies operate in the biotechnology sector with a focus on rare diseases and immunology, yet ALNY emphasizes RNA interference (RNAi) therapeutics while ARGX centers on antibody-based treatments.
- Recent market activity shows ALNY experiencing greater price volatility, including pullbacks from 52-week highs, whereas ARGX has maintained relatively stable performance near its recent peaks.
- Product sales momentum remains a key driver for both, with ALNY reporting significant quarterly revenue increases and ARGX posting substantial growth in its lead therapy.
- Market sentiment reflects differing risk-reward profiles, with ALNY tied to pipeline advancement in ATTR-CM and ARGX benefiting from expanding indications in autoimmune conditions.
- Relative positioning favors ALNY on near-term momentum metrics, though ARGX offers larger market capitalization and established commercial scale.
Introduction
Alnylam Pharmaceuticals (ALNY) and argenx SE (ARGX) represent two prominent biotechnology companies developing therapies for rare and serious diseases. This comparison examines their business models, recent stock behavior, and key performance drivers to assist investors and traders evaluating relative opportunities in the sector. The analysis focuses on observable market data and company developments from recent weeks, providing context for those assessing growth-oriented biotechs or comparing specialized healthcare equities amid evolving market conditions.
ALNY Overview and Recent Performance
Alnylam Pharmaceuticals develops RNA interference (RNAi) therapeutics targeting rare genetic and other serious diseases, with commercial products including treatments for transthyretin-mediated amyloidosis (ATTR). In recent market activity, the stock has shown notable year-to-date gains amid strong product revenue expansion, particularly from AMVUTTRA, though it has also experienced volatility including pullbacks from earlier highs. Sentiment has been influenced by quarterly financial results highlighting revenue growth exceeding 100% year-over-year in the first quarter, alongside pipeline progress in additional indications. Broader market positioning reflects investor attention to commercial execution and upcoming clinical readouts.
ARGX Overview and Recent Performance
argenx SE focuses on antibody-based therapies for autoimmune and inflammatory conditions, with its lead product VYVGART addressing generalized myasthenia gravis (gMG) and other indications. Recent market activity indicates more measured stock performance, with the shares trading near elevated levels after earlier advances and maintaining stability relative to broader sector moves. Developments such as robust first-quarter product sales growth of approximately 63% year-over-year have supported sentiment, while upcoming half-year results scheduled for late July continue to draw attention. The company’s larger market capitalization and established commercial presence have contributed to a comparatively steadier price trajectory in recent weeks.
Trending AI Robots
Tickeron’s Trending AI Robots page curates the highest-performing and most suitable AI trading bots from a library of hundreds that analyze and trade thousands of tickers. Only those demonstrating strong alignment with prevailing market conditions, consistent statistical performance, and appropriate risk parameters earn placement in this section. Available bots span diverse trading styles, strategies, timeframes, and ticker sets, with performance metrics and statistics varying widely across the platform. This selection process highlights opportunities for traders seeking data-driven automation tailored to current environments. Explore the full range at Trending AI Robots.
Head-to-Head Comparison
Alnylam Pharmaceuticals and argenx SE both target high-unmet-need areas within biotechnology but differ in technological approach: ALNY leverages RNAi mechanisms while ARGX utilizes monoclonal and other antibody platforms. Growth drivers for ALNY center on expanding patient uptake in ATTR-CM alongside pipeline maturation, whereas ARGX benefits from label expansions in autoimmune diseases and global commercial scaling. Recent momentum shows ALNY with superior year-to-date returns amid revenue acceleration, contrasted by ARGX’s more contained price movement and larger overall capitalization. Risk factors include clinical and regulatory uncertainties for both, with ALNY exhibiting higher recent volatility. Sector exposure remains concentrated in innovative therapeutics, though market sentiment appears to reward ALNY’s near-term commercial metrics more visibly than ARGX’s steadier profile.
Tickeron AI Verdict
Based on observable factors such as stronger year-to-date trend consistency, revenue growth catalysts, and relative momentum positioning, Tickeron’s AI would currently assign a higher probabilistic preference to ALNY over ARGX in the present environment. This assessment reflects measurable performance differentials rather than forward-looking certainty.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALNY is a Hold and ARGX is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALNY’s FA Score shows that 1 FA rating(s) are green whileARGX’s FA Score has 1 green FA rating(s).
- ALNY’s FA Score: 1 green, 4 red.
- ARGX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALNY’s TA Score shows that 3 TA indicator(s) are bullish while ARGX’s TA Score has 5 bullish TA indicator(s).
- ALNY’s TA Score: 3 bullish, 6 bearish.
- ARGX’s TA Score: 5 bullish, 2 bearish.
Price Growth
ALNY (@Biotechnology) experienced а +1.61% price change this week, while ARGX (@Biotechnology) price change was +6.70% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -4.78%. For the same industry, the average monthly price growth was -3.76%, and the average quarterly price growth was +1901.89%.
Reported Earning Dates
ALNY is expected to report earnings on Jul 30, 2026.
ARGX is expected to report earnings on Oct 22, 2026.
Industries' Descriptions
@Biotechnology (-4.78% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| ALNY | ARGX | ALNY / ARGX | |
| Capitalization | 36.3B | 57.3B | 63% |
| EBITDA | 866M | 1.51B | 57% |
| Gain YTD | -31.656 | 9.188 | -345% |
| P/E Ratio | 68.28 | 34.98 | 195% |
| Revenue | 4.29B | 4.66B | 92% |
| Total Cash | 3.01B | 3.93B | 77% |
| Total Debt | 1.27B | 43.2M | 2,947% |
ALNY | ARGX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 57 | 65 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 89 Overvalued | 82 Overvalued | |
PROFIT vs RISK RATING 1..100 | 74 | 19 | |
SMR RATING 1..100 | 13 | 39 | |
PRICE GROWTH RATING 1..100 | 73 | 40 | |
P/E GROWTH RATING 1..100 | 100 | 53 | |
SEASONALITY SCORE 1..100 | 85 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ARGX's Valuation (82) in the Pharmaceuticals Other industry is in the same range as ALNY (89) in the Biotechnology industry. This means that ARGX’s stock grew similarly to ALNY’s over the last 12 months.
ARGX's Profit vs Risk Rating (19) in the Pharmaceuticals Other industry is somewhat better than the same rating for ALNY (74) in the Biotechnology industry. This means that ARGX’s stock grew somewhat faster than ALNY’s over the last 12 months.
ALNY's SMR Rating (13) in the Biotechnology industry is in the same range as ARGX (39) in the Pharmaceuticals Other industry. This means that ALNY’s stock grew similarly to ARGX’s over the last 12 months.
ARGX's Price Growth Rating (40) in the Pharmaceuticals Other industry is somewhat better than the same rating for ALNY (73) in the Biotechnology industry. This means that ARGX’s stock grew somewhat faster than ALNY’s over the last 12 months.
ARGX's P/E Growth Rating (53) in the Pharmaceuticals Other industry is somewhat better than the same rating for ALNY (100) in the Biotechnology industry. This means that ARGX’s stock grew somewhat faster than ALNY’s over the last 12 months.
| ALNY | ARGX | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 67% | N/A |
| Stochastic ODDS (%) | 1 day ago 68% | 1 day ago 70% |
| Momentum ODDS (%) | 1 day ago 71% | 1 day ago 71% |
| MACD ODDS (%) | 1 day ago 67% | 1 day ago 77% |
| TrendWeek ODDS (%) | 1 day ago 69% | 1 day ago 69% |
| TrendMonth ODDS (%) | 1 day ago 71% | 1 day ago 66% |
| Advances ODDS (%) | 1 day ago 73% | N/A |
| Declines ODDS (%) | 3 days ago 68% | 11 days ago 64% |
| BollingerBands ODDS (%) | 1 day ago 73% | 1 day ago 56% |
| Aroon ODDS (%) | N/A | 1 day ago 74% |
Advertisement
ARGX and
Correlation & Price change
A.I.dvisor indicates that over the last year, ARGX has been loosely correlated with ALNY. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ARGX jumps, then ALNY could also see price increases.
| Ticker / NAME | Correlation To ARGX | 1D Price Change % | ||
|---|---|---|---|---|
| ARGX | 100% | -0.69% | ||
| ALNY - ARGX | 42% Loosely correlated | +1.13% | ||
| AXON - ARGX | 40% Loosely correlated | +2.12% | ||
| MIRM - ARGX | 36% Loosely correlated | -1.16% | ||
| ARRY - ARGX | 36% Loosely correlated | -5.42% | ||
| GMAB - ARGX | 32% Poorly correlated | -1.03% | ||
More | ||||